華堂寧®恢復正常供應,華領醫藥預計2023年實現銷量全面爆發
格隆匯1月13日丨據悉,在京東大藥房、1藥網等互聯網藥店端,華領醫藥(2552.HK)旗下全球首創新藥葡萄糖激酶激活劑(GKA)華堂寧®(多格列艾汀片)在經歷短暫的缺貨後,現已恢復正常供應,時間大大早於此前預期,這對於許多等待使用該藥的患者來説是個重大好消息,他們有望在年前購買到這款具有全新機制的口服藥物。華堂寧®於2022年9月正式獲批,不久前,華堂寧®正式獲編入世衞組織ATC代碼系統,成為該國際權威組織認可的全球範圍內的第10類全新機制的糖尿病口服藥物。針對華領在2023年的市場計劃,華領醫藥藥品營銷部副總裁董清表示,華領醫藥正在與戰略合作伙伴壹藥網共同籌備線上旗艦店,以實現線下、線上銷售相結合,更大範圍的提高患者購藥的便利性,也使其成為華領醫藥更好地服務患者和臨牀醫生的重要平台。華堂寧®也將進一步擴大在醫院和藥房的可及性,有望在年內實現翻倍增長,以極大增加患者購藥的可及性。此外,對於外界關心的醫保問題,華領醫藥正在與合作伙伴共同努力,積極爭取在今年獲得國家醫保談判的機會,目前公司已經開始準備包括藥物經濟學等在內的醫保談判資料。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.